
FINANCIAL INFORMATION OF PROPOSED DISPOSALS AND WITHDRAWAL OF CAUTIONARY

Shareholders are referred to the announcement published on 1 February 2022 advising of the Proposed Disposals for the full recapitalisation of the Company ("1 February Announcement"). The terms used in this announcement bear the same meaning as those defined in the 1 February Announcement.

1. FINANCIAL INFORMATION OF PROPOSED DISPOSALS

The financial information relating to Ascendis Medical, Ascendis Pharma and Nimue, respectively, is shown below:

1.1. Ascendis Medical

The net asset value of Ascendis Medical as at 31 December 2021, being the date of the last published (six month interim) financial information of Ascendis Health, was R289 million. The unaudited loss after tax attributable to Ascendis Medical for the six months ended 31 December 2021 was R259 million.

1.2. Ascendis Pharma

The net asset value of Ascendis Pharma as at 31 December 2021, being the date of the last published (six month interim) financial information of Ascendis Health, was R117 million. The unaudited profit after tax attributable to Ascendis Pharma for the six months ended 31 December 2021 was R22 million.

1.3. Nimue

The net asset value of Nimue as at 31 December 2021, being the date of the last published (six month interim) financial information of Ascendis Health, was R32 million. The unaudited profit after tax attributable to Nimue for the six months ended 31 December 2021 was R5 million.

The financial information was prepared in accordance with International Financial Reporting Standards and the Companies Act, 2008 (Act 71 of 2008), as amended and extracted from the unaudited interim financial statements of Ascendis for the six months ended 31 December 2022. The pro forma financial effects of the Proposed Disposals will be detailed in the Circular referred to in the 1 February Announcement.

2. WITHDRAWAL OF CAUTIONARY

Pursuant to the publication of the financial information contained in paragraph 1 above, Shareholders are advised that caution is no longer required when dealing in their Ascendis Health shares.

The Board accepts responsibility for the information contained in this announcement as it pertains to Ascendis Health. To the best of the Board's knowledge and belief, the information contained in this announcement as it pertains to Ascendis Health is true and nothing has been omitted which is likely to affect the importance of such information.

15 March 2022
Bryanston

Sponsor



Questco Corporate Advisory Proprietary Limited